keyword
MENU ▼
Read by QxMD icon Read
search

mantle lymphoma

keyword
https://www.readbyqxmd.com/read/28095146/phase-i-first-in-human-study-of-venetoclax-in-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma
#1
Matthew S Davids, Andrew W Roberts, John F Seymour, John M Pagel, Brad S Kahl, William G Wierda, Soham Puvvada, Thomas J Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A Humerickhouse, Gary B Gordon, John F Gerecitano
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. Patients and Methods A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts...
January 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28092998/treatment-patterns-and-outcomes-with-subcutaneous-bortezomib-in-patients-with-relapsed-mantle-cell-lymphoma-a-retrospective-observational-study-of-patient-medical-records-from-us-community-oncology-practices
#2
Alan P Skarbnik, Esprit Ma, Marie-Hélène Lafeuille, Jonathan Fortier, Tatyana Feldman, Mei Sheng Duh, Helgi van de Velde, Liviu Niculescu, Vijayveer Bonthapally, André Goy
No abstract text is available yet for this article.
January 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28092871/discrete-vacuoles-in-lymphocytes-as-a-subtle-clue-to-mantle-cell-lymphoma
#3
David T Lynch, Kathryn Foucar
No abstract text is available yet for this article.
June 23, 2016: Blood
https://www.readbyqxmd.com/read/28090306/a-case-of-pulmonary-arterial-hypertension-associated-with-adult-hemophagocytic-lymphohistiocytosis
#4
Julius Koifman, John Granton, John Thenganatt
Hemophagocytic lymphohistiocytosis (HLH) is an aggressive, life-threatening syndrome of excessive immune activation. Presentation is most common among the pediatric population, and cases in adults are rare. The number of nonhematologic presentations described in relation to HLH has been growing. We present a case involving a woman who developed HLH after autologous stem cell transplantation for mantle cell lymphoma. Months later, she received a diagnosis of pulmonary arterial hypertension (PAH) while undergoing treatment for her HLH...
December 2016: Pulmonary Circulation
https://www.readbyqxmd.com/read/28088974/-bortezomib-rituximab-combined-with-chemotherapy-for-mantle-cell-lymphoma-two-cases-report-and-literature-review
#5
J Su, H Xu, X Shi, X F Sui, Z G Cui, H G Zhao
No abstract text is available yet for this article.
December 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/28081018/mantle-cell-lymphoma-presenting-as-a-subcutaneous-soft-tissue-mass-with-an-unusual-appearance
#6
Anjuli R Cherukuri, Vivek Kalia, Norman V Sturtevant, Kristen K DeStigter
No abstract text is available yet for this article.
January 9, 2017: Ultrasound Quarterly
https://www.readbyqxmd.com/read/28066928/predictive-factors-and-outcomes-for-ibrutinib-therapy-in-relapsed-refractory-mantle-cell-lymphoma-a-real-world-study
#7
Narendranath Epperla, Mehdi Hamadani, Amanda F Cashen, Kwang W Ahn, Eunhye Oak, Abraham S Kanate, Oscar Calzada, Jonathon B Cohen, Luke Farmer, Nilanjan Ghosh, Michael Tallarico, Chadi Nabhan, Luciano J Costa, Vaishalee P Kenkre, Parameswaran N Hari, Timothy S Fenske
Ibrutinib has demonstrated significant activity in relapsed/refractory mantle cell lymphoma (MCL) in clinical trials. However, the impact of hematopoietic cell transplantation on the outcomes of ibrutinib and the predictive factors for ibrutinib response has not been well studied. Hence, we conducted a multicenter retrospective study of MCL patients who received ibrutinib to (1) determine the overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) of ibrutinib in routine clinical practice, (2) examine characteristics predictive of response to ibrutinib therapy, and (3) describe the outcomes of patients failing ibrutinib...
January 8, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28063897/mantle-cell-lymphoma-with-central-nervous-system-involvement-simulating-bilateral-subdural-hematomas
#8
Luis Germán González-Bonet, Raimundo García-Boyero, John Gaona-Morales
No abstract text is available yet for this article.
January 4, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28062425/first-reported-case-of-disseminated-nocardia-kroppenstedtii-sp-nov-infection-presenting-with-brain-abscess-and-endocarditis-in-an-immunocompromised-patient-with-mantle-cell-lymphoma-challenges-in-diagnosis-and-treatment
#9
Aneela Majeed, Hafez Mohammad Ammar Abdullah, Waqas Ullah, Mayar Al Mohajer
A 72-year-old man with a history of blastoid variant stage IV relapsed refractory mantle cell lymphoma presented with new central nervous system (CNS) symptoms. Brain imaging was positive for rim-enhancing lesions along with a mitral valve mass on the echocardiogram. It was a challenge to establish the exact aetiology of these lesions in this patient. He was empirically treated with chemotherapy on the presumption that the brain lesions were secondary to progressive malignancy. However, brain biopsy was negative for malignancy and blood cultures were found positive for Nocardia kroppenstedtii sp nov...
January 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28056186/tampering-with-cancer-chemoresistance-by-targeting-the-tgm2-il6-autophagy-regulatory-network
#10
Han Zhang, Nami McCarty
Macroautophagy/autophagy is a well-established process involved in maintaining cellular homeostasis, but its role in cancer is complex and even controversial. Many studies have reported a correlative relationship between increased autophagy and evolving cancer cells under stress conditions such as nutrient or oxygen deprivation; however, there has been a lack of a plausible mechanistic link to properly target the autophagy process in the context of this microenvironment. We recently unveiled a positive regulatory loop involving TGM2 (transglutaminase 2)-NFKB/NF-κB signaling, IL6 and autophagy in cancer using mantle cell lymphoma (MCL) as a model system...
January 5, 2017: Autophagy
https://www.readbyqxmd.com/read/28055107/results-of-a-phase-i-ii-study-of-fenretinide-and-rituximab-for-patients-with-indolent-b-cell-lymphoma-and-mantle-cell-lymphoma
#11
Andrew J Cowan, Phillip A Stevenson, Ted A Gooley, Shani L Frayo, George R Oliveira, Stephen D Smith, Damian J Green, Jennifer E Roden, John M Pagel, Brent L Wood, Oliver W Press, Ajay K Gopal
Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I-II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mantle cell lymphoma. The phase I design de-escalated from fenretinide at 900 mg/m(2) PO BID for days 1-5 of a 7-day cycle. The phase II portion added 375 mg/m(2) IV rituximab weekly on weeks 5-9 then every 3 months...
January 5, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28040733/recommendations-for-clinical-trial-development-in-mantle-cell-lymphoma
#12
REVIEW
Stephen E Spurgeon, Brian G Till, Peter Martin, Andre H Goy, Martin P Dreyling, Ajay K Gopal, Michael LeBlanc, John P Leonard, Jonathan W Friedberg, Lawrence Baizer, Richard F Little, Brad S Kahl, Mitchell R Smith
Mantle cell lymphoma (MCL) comprises around 6% of all non-Hodgkin's lymphoma (NHL) diagnoses. In younger patients, age less than 60 to 65 years, aggressive induction often followed by consolidation with autologous stem cell transplant has suggested improved outcomes in this population. Less intensive therapies in older patients often followed by maintenance have been studied or are under active investigation. However, despite recent advances, MCL remains incurable, with a median overall survival of around five years...
January 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28039078/molecular-monitoring-after-autologous-stem-cell-transplantation-and-preemptive-rituximab-treatment-of-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-8-5-years
#13
Arne Kolstad, Lone Bredo Pedersen, Christian W Eskelund, Simon Husby, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, Niels Smedegaard Andersen, Peter deNully Brown, Eva Kimby, Hans Bentzen, Christer Sundström, Mats Ehinger, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, Elisabeth Ralfkiær, Unn-Merete Fagerli, Herman Nilsson-Ehle, Grete Fossum Lauritzsen, Outi Kuittinen, Carsten Niemann, Christian Hartman Geisler
The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in the our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements...
December 27, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28038713/expression-of-lef1-in-mantle-cell-lymphoma
#14
Dennis P O'Malley, John P Lee, Andrew M Bellizzi
Small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL) and mantle cell lymphoma (MCL) usually are distinctly different in regard to clinical presentation, morphology, immunophenotype and molecular/genetic findings. In spite of this, select cases may show overlapping characteristics and represent a diagnostic challenge. Recently LEF1 staining was identified as a fairly characteristic finding in CLL/SLL, with positivity identified in up to 95% of cases. LEF1 staining has not been reported as being present in cases of MCL, making this stain a useful tool in distinguishing these diagnoses...
February 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28038705/cyclin-d1-expression-and-polysomy-in-lymphocyte-predominant-cells-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#15
Benjamin B Cho, Sarah M Kelting, Alejandro A Gru, Robin D LeGallo, Patcharin Pramoonjago, Teresa A Goldin, Christopher T Heitz, Nadine S Aguilera
Cyclin D1 protein expression in lymphocytes is classically associated with mantle cell lymphoma. Although increasingly recognized in other lymphoproliferative disorders, cyclin D1 expression and CCND1 gene abnormalities have not been well studied in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Using a double stain for CD20/cyclin D1, we quantified cyclin D1 expression in 10 cases of NLPHL and correlated those findings with SOX11 expression, CCND1 gene abnormalities, and clinical data. For comparison, we examined 5 cases of T cell-/histiocyte-rich large B-cell lymphoma (THRLBCL)...
February 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28035065/zgdhu-1-promotes-apoptosis-of-mantle-cell-lymphoma-cells
#16
Liannv Qiu, Jinlin Liu, Zhenni Wang, Sufeng Chen, Weixiao Hu, Qiang Huang, Yonglie Zhou
Mantle cell lymphoma (MCL) is a well-defined aggressive Non-Hodgkin-lymphoma with short survival rates and remains incurable to date. Previously, we demonstrated the antitumor activity of ZGDHu-1(N, N'-di-(m-methylphenyi)-3, 6-dimethyl-1, 4-dihydro-1, 2, 4, 5-tetrazine-1, 4-dicarboamide) in chronic lymphocytic leukemia. In this study, ZGDHu-1 shows potent anti-lymphoma activity in MCL cells. ZGDHu-1 significantly induces cell cycle G2/M phase arrest and apoptosis in MCL cells. ZGDHu-1 reduces the protein levels of Mcl-1, Bcl-XL and cyclin D1...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/28032914/pleomorphic-mantle-cell-lymphoma-morphologically-mimicking-diffuse-large-b-cell-lymphoma-common-cyclin-d1-negativity-and-a-simple-immunohistochemical-algorithm-to-avoid-the-diagnostic-pitfall
#17
Wen-Yu Chuang, Hung Chang, Gwo-Jyh Chang, Tzu-Hao Wang, Yu-Sun Chang, Tong-Hong Wang, Chi-Ju Yeh, Shir-Hwa Ueng, Hui-Ping Chien, Chiu-Yueh Chang, Yung-Liang Wan, Chuen Hsueh
AIMS: To characterize the clinicopathologic and genetic features of pleomorphic mantle cell lymphoma (PMCL) which morphologically mimics diffuse large B-cell lymphoma (DLBCL). METHODS AND RESULTS: We systematically screened 500 B-cell lymphomas morphologically compatible with DLBCL using an immunohistochemical algorithm of three markers (CD5, cyclin D1 and SOX11). Ten cases of PMCL were identified for further study, and surprisingly four (40%) of them were cyclin D1-negative...
December 29, 2016: Histopathology
https://www.readbyqxmd.com/read/28031660/a-rare-case-of-gastric-mantle-cell-lymphoma-causing-superior-mesenteric-artery-syndrome-in-an-adult
#18
Shailesh Garg, Alain Derzie
Superior mesenteric artery (SMA) syndrome or Wilkie syndrome is a rare condition that arises when the distal third of the duodenum becomes trapped between the SMA and the abdominal aorta causing intestinal obstruction. It is most commonly described in adolescents and rarely in adult patients. We present an interesting case of an adult who developed SMA syndrome from an uncommon gastric mantle cell lymphoma that was recognized early and treated surgically.
December 2016: International Journal of Angiology: Official Publication of the International College of Angiology, Inc
https://www.readbyqxmd.com/read/28028120/ccnd1-igh-fusion-amplification-and-myc-copy-number-gain-in-a-case-of-pleomorphic-variant-mantle-cell-lymphoma
#19
Yuan Miao, Pei Lin, Wei Wang, L Jeffrey Medeiros, Xinyan Lu
OBJECTIVES: Mantle cell lymphoma (MCL) may present de novo or undergo progression to a clinically aggressive variant, known as a blastoid or pleomorphic variant. We report an unusual case of classic MCL in a 78-year-old man with a typical immunophenotype, including CD5 positivity, who subsequently relapsed with CD5-negative pleomorphic variant MCL. METHODS: Biopsy specimens were evaluated using Wright-Giemsa-stained or H&E-stained sections, flow cytometry, immunohistochemistry, conventional cytogenetic, next-generation sequencing, and fluorescence in situ hybridization...
December 27, 2016: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28024628/polypropyleneimine-and-polyamidoamine-dendrimer-mediated-enhanced-solubilization-of-bortezomib-comparison-and-evaluation-of-mechanistic-aspects-by-thermodynamics-and-molecular-simulations
#20
Sonam Chaudhary, Avinash Gothwal, Iliyas Khan, Shubham Srivastava, Ruchi Malik, Umesh Gupta
Bortezomib (BTZ) is the first proteasome inhibitor approved by the US-FDA is majorly used for the treatment of newly diagnosed and relapsed multiple myeloma including mantle cell lymphoma. BTZ is hydrophobic in nature and is a major cause for its minimal presence as marketed formulations. The present study reports the design, development and characterization of dendrimer based formulation for the improved solubility and effectivity of bortezomib. The study also equally focuses on the mechanistic elucidation of solubilization by two types of dendrimers i...
March 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
keyword
keyword
38851
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"